Table 4

Modelled lifetime cost breakdown of different strategies (all values in euros)

	Adalimumab >+MTX (DE009)	Adalimumab >+MTX >(DE009 and DE019)	Etanercept >+MTX	Infliximab >+MTX	Adalimumab monotherapy	Etanercept monotherapy	Traditional DMARDs
ACR50/DAS28 good
Drug	48948	41407	41140	29859	24706	39423	3962
Direct	39317	40479	41271	48863	44153	41507	46145
Monitoring/adverse events	20717	20723	20718	23376	21199	21491	20280
Total cost	108982	102610	103129	102099	90058	102421	70387
Total QALY	2.3114	2.1045	2.0974	1.8379	1.6551	2.0493	1.1818
Incremental cost v traditional DMARD	38595	32222	32742	31711	19671	32034	–
Incremental QALY v traditional DMARD	1.1296	0.9227	0.9156	0.6560	0.4733	0.8675	–
Incremental cost per QALY v traditional DMARD	34167	34922	35760	48333	41561	36927	–

ACR20/DAS28 moderate
Drug	61306	56853	65517	44247	43860	55042	5816
Direct	36246	37186	44611	45371	48721	36988	43218
Monitoring/adverse events	20428	20424	23462	25114	23861	20320	19724
Total cost	117979	114462	133590	114732	116442	112351	68757
Total QALY	2.9083	2.7424	2.9515	2.4121	2.4321	2.7303	1.7041
Incremental cost v traditional DMARD	49221	45705	64832	45974	47685	43593	–
Incremental QALY v traditional DMARD	1.2042	1.0383	1.2474	0.7080	0.7280	1.0262	–
Incremental cost per QALY v traditional DMARD	40875	44018	51976	64935	65499	42480	–